BIO praises House for approving H.R. 307.January 29, 2013 -
According to BIO's Jim Greenwood, H.R. 307, Pandemic and All-Hazards Preparedness Reauthorization Act is an opportunity to build more prepared and resilient communities that are better able to withstand natural disasters, bioterrorist attacks, and infectious disease outbreaks. Bipartisan legislation will help advance medical countermeasure development through increased coordination among agencies, more transparent and consistent regulatory process, and continued commitment of government funding.
BIO Praises The House of Representatives for Approving H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act |
Biotechnology Industry Organization
1201 Maryland Ave., SW, Ste. 900
Washington, DC, 20024
USA
Press release date: January 24, 2013
Bill will accelerate R&D to help support nation’s preparedness against chemical, biological, radiological and nuclear threats
WASHINGTON -- The Biotechnology Industry Organization lauds the House of Representatives for passing H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), today by a vote of 395-29. BIO also commends Rep. Mike Rogers (R-MI) and Rep. Gene Green (D-TX) for their leadership on this very important issue.
Below is a statement from BIO’s President and CEO, Jim Greenwood:
The reauthorization of PAHPA is an opportunity to build more prepared and resilient communities that are better able to withstand natural disasters, bioterrorist attacks, and outbreaks of infectious disease. We applaud the House for demonstrating its commitment to improving our nation’s capacity to prepare and respond to such significant events.
The original PAHPA legislation represented a major step in developing the role of America’s public health and medical systems in preparing for, and responding to, major emergencies, whether natural or man-made. As evidenced by the recent, widespread destruction of Hurricane Sandy, our nation faces continuing threats, both natural and man-made, that require an ongoing commitment to health preparedness.
The bipartisan legislation will help advance medical countermeasure (MCM) development through increased coordination among agencies, a more transparent and consistent regulatory process and continued commitment of government funding to incentivize industry to develop these countermeasures for which the federal government is the only customer.
Our members play a central role in ensuring the effective development of MCMs to protect our nation’s citizens against chemical, biological, radiological and nuclear threats, whether naturally occurring or man-made.
Strengthening the pipeline of medical products, drugs and devices that will safeguard the nation during an emergency or pandemic is vital to our national security.
The legislation contains important innovations in pediatric preparedness and pediatric MCM development, which were lacking in the original law. We also applaud provisions for advancing biosurveillance planning, as we face a new paradigm in health information. The basic programs that promote preparedness at the federal, state, local, and health system level need reauthorization and implementation.
Passage of PAHPRA demonstrates our nation’s commitment to prioritizing health preparedness and response as we do when confronted by other national security issues. PAHPRA enables the stable frontline response of the public health and healthcare systems, rather than funding on an emergency-by-emergency basis.
We thank the House for quickly considering, and passing, this reauthorization, and we look forward to working with the Senate to see a PAHPA reauthorization enacted as early as possible this year.
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.
Upcoming BIO Events
BIO Asia International Conference
January 29 – 30, 2013
Tokyo, Japan
BIO CEO & Investor Conference
February 11 – 12, 2013
New York City, NY
BIO IPCC Conference
March 25-27, 2013
San Diego, CA
BIO International Convention
April 22 – 25, 2013
Chicago, IL
World Congress on Industrial Biotechnology
June 16-19, 2013
Montreal, Canada
Contacts
Biotechnology Industry Organization
Tracy Cooley, APR
202-312-9274
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
|
|
|
|
|
|
|
|
|
|
|
